IceCure Medical Ltd (NASDAQ: ICCM) shares are experiencing a remarkable surge, soaring 105.35% to $1.14 in pre-market trading at last check. On Friday, IceCure stock closed at $0.55 with a modest 0.02% increase. The remarkable upswing follows favorable evaluations of ICCM’s technology in an independent research study.
What ICCM Technology Was Positively Reviewed?
IceCure (ICCM) is a trailblazer in medical innovation, celebrated for its development of the ProSense System, a groundbreaking technology that offers a minimally invasive cryoablation approach for tumor removal.
This innovative approach, presented at the European Society of Breast Imaging (“EUSOBI”) Scientific Meeting in Valencia, Spain, by Dr. Lucía Graña-López, MD, PhD, highlights the potential of cryoablation as an alternative to traditional surgical methods for early-stage breast cancer treatment.
Dr. Graña-López’s independent study, conducted at the University Hospital Lucus Augusti in Lugo, Spain, focused on 31 patients who declined surgery for various reasons and instead opted for cryoablation using the ProSense System. With a median tumor size of 24 mm, all patients had biopsy-proven early breast cancer.
The patients were rigorously monitored for up to 40 months, and remarkably, only one patient experienced cancer progression, with no major complications reported in the others.
This study underscores cryoablation as a viable alternative for breast cancer patients who choose not to undergo surgery, particularly among the elderly population. Dr. Graña-López’s proficient use of ProSense suggests a promising future where cryoablation may replace surgery as the preferred treatment for post-menopausal women with early-stage breast cancer.
Moreover, ProSense’s potential extends to transforming the treatment landscape for cancers affecting the kidney, lung, and thyroid gland.
How ProSense Will Help ICCM Excel?
The global adoption of ProSense by medical practitioners, especially in the context of early-stage breast cancer, demonstrates its efficacy. The dissemination of these findings by dedicated physicians within the medical community is encouraging.
These findings correspond with the continuous ICE3 investigation conducted by ICCM, the most extensive of its type in the United States, anticipated to be finalized in the initial three months of 2024. This innovative method not only provides optimism to individuals with breast cancer but also possesses the capacity to transform cancer therapy across diverse bodily parts, signifying a substantial progression in the domain of medical knowledge.
